Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (561-570 of 575) with videos related to

Pageof 58
Sort By:
Nature Communications|August 6, 2025
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progressionLeo Carl Foerster, Oguzhan Kaya, Valentin Wüst, et al.
Nature Communications|February 2, 2023
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapyMarcel P Trefny, Nicole Kirchhammer, Priska Auf der Maur, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
JAMA|June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical TrialJamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Nature Genetics|July 3, 2013
An atlas of over 90,000 conserved noncoding sequences provides insight into crucifer regulatory regionsAnnabelle Haudry, Adrian E Platts, Emilio Vello, et al.
Scientific Data|December 18, 2024
Active and passive organic carbon fluxes during a bloom in the Southern Ocean (South Georgia)William Major, Sarah L C Giering, Joanna Ainsworth, et al.
Pageof 58

Showing results (561-570 of 575) with videos related to

Sort By:
Pageof 58
Nature Communications|August 6, 2025
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progressionLeo Carl Foerster, Oguzhan Kaya, Valentin Wüst, et al.
Nature Communications|February 2, 2023
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapyMarcel P Trefny, Nicole Kirchhammer, Priska Auf der Maur, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
JAMA|June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical TrialJamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
Nature Medicine|January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trialAlicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Nature Genetics|July 3, 2013
An atlas of over 90,000 conserved noncoding sequences provides insight into crucifer regulatory regionsAnnabelle Haudry, Adrian E Platts, Emilio Vello, et al.
Scientific Data|December 18, 2024
Active and passive organic carbon fluxes during a bloom in the Southern Ocean (South Georgia)William Major, Sarah L C Giering, Joanna Ainsworth, et al.
Pageof 58